Developer docs
API playgroundTry for free, no card

Search company profiles

INNOTERE

Full company profile

uuid000bfy9

Namestring
INNOTERE
Legal namestring
INNOTERE GmbH
Websiteurl
innotere.de
Company typeenum
Private
Founded yearint
2005
Descriptiontext

INNOTERE GmbH is a German developer and manufacturer of calcium phosphate-based biomaterials and medical devices for bone repair and regeneration, headquartered at Pharmapark Radebeul (Meissner Strasse 191, Germany). Founded in 2004, the company operates a proprietary, patented technology platform that transforms calcium phosphate cements into ready-to-use medical devices, organized across three product families: Medical Devices (Paste-CPC injectable bone cement paste, macroporous 3D Scaffolds, and Patient Specific Implants derived from CT data), Biomaterials (high-purity alpha-TCP, beta-TCP, and hydroxyapatite powders), and 3D Printing consumables (Plotter-Paste-CPC, cell culture scaffolds). It also maintains a parallel veterinary product line and offers regulatory and quality management consulting based on its Class III certification experience.

The company sells primarily through direct, contact-based sales to hospitals, orthopedic clinics, veterinary practices, and academic research institutions globally, with a stated global footprint in 3D printing equipment and biomaterials supply. INNOTERE is certified to EN ISO 13485 and is the first and only company with MDR 2017/745 certification in Class III for a 3D-printed scaffold product family, representing a defensible regulatory position. In October 2025, INNOTERE was integrated into Heraeus Medical's regenerative orthopedics portfolio, bringing its cement and 3D-printed scaffold capabilities under a major global orthopedics platform. Prior to the integration, INNOTERE was a privately held GmbH with 11–50 employees and limited public financial disclosure.

Short descriptiontext

INNOTERE GmbH is a German developer and manufacturer of proprietary calcium phosphate bone cements, 3D-printed scaffolds, and patient-specific implants for orthopedic and veterinary bone repair, certified to MDR Class III and integrated into Heraeus Medical in October 2025.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersRadebeul, Germany
HQ citystring
Radebeul
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
calcium phosphate bone cement, orthobiologics manufacturing, bone graft substitutes, 3D printed scaffolds, patient specific implants
Industry5 codes
PRIMARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHAEAJ
3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAMANAC
Tissue Engineering & Biomaterial Scaffolds
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
SECONDARYIMAAADAG
Medical & Dental 3D Printing Services (patient-specific devices, dental labs)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Services (On-Demand Manufacturing & Service Bureaus)
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Orthobiologic Bone Replacement Materials
Social media profiles1 record
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

INNOTERE GmbH develops and manufactures calcium phosphate-based bone substitute materials and 3D-printed scaffolds for human and veterinary orthopedics. Its portfolio spans ready-to-use injectable Paste-CPC bone cement, macroporous 3D scaffolds, patient-specific implants derived from CT data, and medical-grade calcium phosphate powders (Alpha-TCP, Beta-TCP, Hydroxyapatite). The company also supplies 3D-printing materials and offers medical device regulatory consulting.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Compressive strength up to 35 MPa within a few days after application
+2 more records
Product overview1 text field

INNOTERE is a key contributor in orthobiologics development and manufacturing, specializing in innovative calcium phosphate-based cements. The company operates as a unified product platform built around proprietary calcium phosphate cement technology, organized into three main product families: Medical Devices (Paste-CPC, 3D Scaffold, Patient Specific Implants), Biomaterials (Alpha-TCP, Beta-TCP, Hydroxyapatite), and 3D Printing (Plotter-Paste-CPC, Cell Culture Scaffolds). A dedicated Veterinary line mirrors these products for animal health applications. The company also offers consulting services leveraging over 10 years of MDR Class III certification experience for 3D-printed scaffolds. In October 2025, INNOTERE was integrated into Heraeus Medical's regenerative orthopedics portfolio.

Product and service13 records
1INNOTERE Paste-CPC
CategoryMedical Devices - Bone Cements
Description

Ready-to-use injectable calcium phosphate bone cement paste for bone void filling in human and veterinary orthopedic surgery. Sets only after contact with aqueous liquids, eliminating intraoperative time pressure.

2INNOTERE 3D Scaffold
CategoryMedical Devices - Bone Grafts
Description

Macroporous, synthetic, biocompatible, osteoconductive and bioresorbable 3D-printed calcium phosphate scaffold for guided bone regeneration in human and veterinary orthopedic surgery.

3INNOTERE Patient Specific Implants (PSI)
CategoryMedical Devices - Custom Implants
Description

Patient-specific, apatitic implants for reconstructing or supporting individual bone defects, manufactured from CT data with customizable macroporosity and geometry per surgeon requirements.

4Alpha-Tricalcium Phosphate (Alpha-TCP)
CategoryBiomaterials - Calcium Phosphates
Description

Medical-grade alpha-tricalcium phosphate powder with >99% phase purity and batch-to-batch reproducibility, used in bone cements, bone graft substitutes, coatings, and 3D printing.

5Beta-Tricalcium Phosphate (Beta-TCP)
CategoryBiomaterials - Calcium Phosphates
Description

Medical-grade beta-tricalcium phosphate powder with >98% phase purity, providing an ideal scaffold for bone regeneration with balanced resorption behavior.

6Hydroxyapatite
CategoryBiomaterials - Calcium Phosphates
Description

Highly bioactive, medical-grade hydroxyapatite supplied in granules and fine powder forms, manufactured from alpha-TCP-based cement using INNOTERE's innovative 3D-printing process.

7Plotter-Paste-CPC
Category3D Printing Materials
Description

Calcium phosphate cement paste for 3D extrusion printing of compact or porous scaffolds with high dimensional accuracy, used as a 3D-printing consumable material.

8Cell Culture Scaffolds
Category3D Printing - Research Products
Description

Ready-packaged, gamma-sterilized calcium phosphate scaffolds with interconnected porosity available in standardized 2D and 3D geometries for cell culture research in bone regeneration.

9INNOTERE Veterinary Paste-CPC
CategoryVeterinary - Bone Substitutes
Description

Ready-to-use, self-setting synthetic calcium phosphate bone substitute for minimally invasive application in veterinary orthopedic surgery.

10INNOTERE Veterinary Granules
CategoryVeterinary - Bone Substitutes
Description

Highly uniform calcium phosphate granules manufactured via INNOTERE's 3D-printing process for veterinary bone substitution applications.

11INNOTERE Veterinary Scaffolds
CategoryVeterinary - Bone Substitutes
Description

3D-printed calcium phosphate scaffolds offered in cylindrical, cubic, or wedge shapes in various sizes for veterinary bone regeneration applications.

12INNOTERE Veterinary Powder-CPC
CategoryVeterinary - Bone Substitutes
Description

Calcium phosphate powder with mixing syringe for preparation of injectable bone substitute with optional antibiotic release properties for veterinary use.

13Medical Device Consulting Services
CategoryServices - Regulatory Consulting
Description

Consulting services covering conceptual design, technical documentation, MDR 2017/745 compliance, quality management system establishment, and certification support for orthobiologic medical device manufacturers.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

Heraeus Medical expanded its regenerative orthopedics portfolio in October 2025 through integration of INNOTERE GmbH. This integration brought INNOTERE's calcium phosphate cement technology and 3D-printed scaffold capabilities into Heraeus Medical's portfolio, strengthening their position in orthobiologics.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

TheraVet SA previously distributed INNOTERE's veterinary products exclusively under the trade names BIOCERA-VET Bone Surgery RTU, BIOCERA-VET Bone Surgery Equine, BIOCERA-VET Bone Surgery Granules, and BIOCERA-VET Osteosarcoma RTU. Products are now offered under INNOTERE Veterinary brand.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Dutch company specializing in 3D-printed patient-specific implants for cranial, orthopedic, and reconstructive surgery. Direct peer to INNOTERE's Patient-Specific Implants offering.

TypeBroad incumbent
Description

Global orthopedic medical device leader with a broad orthobiologics portfolio (bone graft substitutes, regenerative materials). Comparable as a large incumbent selling into the same hospital channels as INNOTERE.

TypeBroad incumbent
Description

Pure-play orthobiologics company offering bone graft substitutes, hyaluronic acid, and ultrasonic bone healing products. Comparable as a focused orthobiologics incumbent competing in bone repair and regeneration.

4Kasios
TypeDirect peer
Description

French manufacturer of synthetic bone graft substitutes including calcium phosphate cements and TCP-based products for spine, trauma, and dental surgery. Direct peer in synthetic bone void fillers.

TypeDirect peer
Description

German manufacturer of bone regeneration materials, including synthetic bone graft substitutes and dental bone replacement products. Comparable to INNOTERE's bone void-filler portfolio with a focus on dental/orthopedic use.

6Biomatlante
TypeDirect peer
Description

Specialist in calcium phosphate-based bone substitutes and macroporous scaffolds for orthopedic and dental surgery. Closely comparable to INNOTERE's calcium phosphate cement and 3D scaffold portfolio.

TypeDirect peer
Description

French manufacturer of synthetic calcium phosphate bone graft substitutes (MBCP technology) for orthopedic, spinal, and dental indications. Direct peer given shared calcium phosphate cement platform and bone void-filler focus.

TypeDirect peer
Description

Finnish company producing bioactive glass and synthetic bone graft substitutes for orthopedic and dental bone regeneration. Comparable as a niche European synthetic bone-substitute specialist.

9Botiss Biomaterials
TypeDirect peer
Description

Provider of bone and soft tissue regeneration materials, including synthetic bone graft substitutes and 3D-printed scaffolds for dental and orthopedic applications. Direct overlap in synthetic bone substitutes and 3D scaffolds.

TypeBroad incumbent
Description

Diversified medical device giant with a substantial orthobiologics and spine business, including bone graft substitutes. Comparable as a broad incumbent competing in the same bone repair indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

INNOTERE

Orthobiologic Bone Replacement Materialsinnotere.de

INNOTERE GmbH is a German developer and manufacturer of proprietary calcium phosphate bone cements, 3D-printed scaffolds, and patient-specific implants for orthopedic and veterinary bone repair, certified to MDR Class III and integrated into Heraeus Medical in October 2025.

What INNOTERE does

INNOTERE GmbH is a German developer and manufacturer of calcium phosphate-based biomaterials and medical devices for bone repair and regeneration, headquartered at Pharmapark Radebeul (Meissner Strasse 191, Germany). Founded in 2004, the company operates a proprietary, patented technology platform that transforms calcium phosphate cements into ready-to-use medical devices, organized across three product families: Medical Devices (Paste-CPC injectable bone cement paste, macroporous 3D Scaffolds, and Patient Specific Implants derived from CT data), Biomaterials (high-purity alpha-TCP, beta-TCP, and hydroxyapatite powders), and 3D Printing consumables (Plotter-Paste-CPC, cell culture scaffolds). It also maintains a parallel veterinary product line and offers regulatory and quality management consulting based on its Class III certification experience.

The company sells primarily through direct, contact-based sales to hospitals, orthopedic clinics, veterinary practices, and academic research institutions globally, with a stated global footprint in 3D printing equipment and biomaterials supply. INNOTERE is certified to EN ISO 13485 and is the first and only company with MDR 2017/745 certification in Class III for a 3D-printed scaffold product family, representing a defensible regulatory position. In October 2025, INNOTERE was integrated into Heraeus Medical's regenerative orthopedics portfolio, bringing its cement and 3D-printed scaffold capabilities under a major global orthopedics platform. Prior to the integration, INNOTERE was a privately held GmbH with 11–50 employees and limited public financial disclosure.

INNOTERE firmographics

Firmographics
Name
INNOTERE
Legal name
INNOTERE GmbH
Website
https://innotere.de
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
1–10 employees
Short description
INNOTERE GmbH is a German developer and manufacturer of proprietary calcium phosphate bone cements, 3D-printed scaffolds, and patient-specific implants for orthopedic and veterinary bone repair, certified to MDR Class III and integrated into Heraeus Medical in October 2025.
Ownership category
akta.pro rank

INNOTERE industry classification

Industry
Product category
Orthobiologic Bone Replacement Materials
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHAEAJ
3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAMANAC
Tissue Engineering & Biomaterial Scaffolds
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
SECONDARYIMAAADAG
Medical & Dental 3D Printing Services (patient-specific devices, dental labs)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Services (On-Demand Manufacturing & Service Bureaus)

Keywords

  • Calcium phosphate bone cement
  • Orthobiologics manufacturing
  • Bone graft substitutes
  • 3D printed scaffolds
  • Patient specific implants

Where INNOTERE is headquartered

Location

Headquarters

HQ city
Radebeul
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

INNOTERE business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales

Distribution channels3 records

Marketing channels4 records

INNOTERE product offering

Product offering

Core offering

INNOTERE GmbH develops and manufactures calcium phosphate-based bone substitute materials and 3D-printed scaffolds for human and veterinary orthopedics. Its portfolio spans ready-to-use injectable Paste-CPC bone cement, macroporous 3D scaffolds, patient-specific implants derived from CT data, and medical-grade calcium phosphate powders (Alpha-TCP, Beta-TCP, Hydroxyapatite). The company also supplies 3D-printing materials and offers medical device regulatory consulting.

Product overview

INNOTERE is a key contributor in orthobiologics development and manufacturing, specializing in innovative calcium phosphate-based cements. The company operates as a unified product platform built around proprietary calcium phosphate cement technology, organized into three main product families: Medical Devices (Paste-CPC, 3D Scaffold, Patient Specific Implants), Biomaterials (Alpha-TCP, Beta-TCP, Hydroxyapatite), and 3D Printing (Plotter-Paste-CPC, Cell Culture Scaffolds). A dedicated Veterinary line mirrors these products for animal health applications. The company also offers consulting services leveraging over 10 years of MDR Class III certification experience for 3D-printed scaffolds. In October 2025, INNOTERE was integrated into Heraeus Medical's regenerative orthopedics portfolio.

Differentiator

Problem solved

Functional benefit

Products and services

  • INNOTERE Paste-CPC Ready-to-use injectable calcium phosphate bone cement paste for bone void filling in human and veterinary orthopedic surgery. Sets only after contact with aqueous liquids, eliminating intraoperative time pressure.
  • INNOTERE 3D Scaffold Macroporous, synthetic, biocompatible, osteoconductive and bioresorbable 3D-printed calcium phosphate scaffold for guided bone regeneration in human and veterinary orthopedic surgery.
  • INNOTERE Patient Specific Implants (PSI) Patient-specific, apatitic implants for reconstructing or supporting individual bone defects, manufactured from CT data with customizable macroporosity and geometry per surgeon requirements.
  • Alpha-Tricalcium Phosphate (Alpha-TCP) Medical-grade alpha-tricalcium phosphate powder with >99% phase purity and batch-to-batch reproducibility, used in bone cements, bone graft substitutes, coatings, and 3D printing.
  • Beta-Tricalcium Phosphate (Beta-TCP) Medical-grade beta-tricalcium phosphate powder with >98% phase purity, providing an ideal scaffold for bone regeneration with balanced resorption behavior.
  • Hydroxyapatite Highly bioactive, medical-grade hydroxyapatite supplied in granules and fine powder forms, manufactured from alpha-TCP-based cement using INNOTERE's innovative 3D-printing process.
  • Plotter-Paste-CPC Calcium phosphate cement paste for 3D extrusion printing of compact or porous scaffolds with high dimensional accuracy, used as a 3D-printing consumable material.
  • Cell Culture Scaffolds Ready-packaged, gamma-sterilized calcium phosphate scaffolds with interconnected porosity available in standardized 2D and 3D geometries for cell culture research in bone regeneration.
  • INNOTERE Veterinary Paste-CPC Ready-to-use, self-setting synthetic calcium phosphate bone substitute for minimally invasive application in veterinary orthopedic surgery.
  • INNOTERE Veterinary Granules Highly uniform calcium phosphate granules manufactured via INNOTERE's 3D-printing process for veterinary bone substitution applications.
  • INNOTERE Veterinary Scaffolds 3D-printed calcium phosphate scaffolds offered in cylindrical, cubic, or wedge shapes in various sizes for veterinary bone regeneration applications.
  • INNOTERE Veterinary Powder-CPC Calcium phosphate powder with mixing syringe for preparation of injectable bone substitute with optional antibiotic release properties for veterinary use.
  • Medical Device Consulting Services Consulting services covering conceptual design, technical documentation, MDR 2017/745 compliance, quality management system establishment, and certification support for orthobiologic medical device manufacturers.

Quantifiable outcome

  • Compressive strength up to 35 MPa within a few days after application
  • +2 more outcomes

Companies that use INNOTERE

Customer profile

Segments4 records

Ideal customer profiles4 records

INNOTERE technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

INNOTERE partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered major and minor.

  • Heraeus MedicalmajorStrategic or Co-development Partner · 1 October 2025Heraeus Medical expanded its regenerative orthopedics portfolio in October 2025 through integration of INNOTERE GmbH. This integration brought INNOTERE's calcium phosphate cement technology and 3D-printed scaffold capabilities into Heraeus Medical's portfolio, strengthening their position in orthobiologics.
  • TheraVet SAminorChannel Partner/ Reseller/ DistributorTheraVet SA previously distributed INNOTERE's veterinary products exclusively under the trade names BIOCERA-VET Bone Surgery RTU, BIOCERA-VET Bone Surgery Equine, BIOCERA-VET Bone Surgery Granules, and BIOCERA-VET Osteosarcoma RTU. Products are now offered under INNOTERE Veterinary brand.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

INNOTERE competitors and assessment

Company assessment

Direct peers

  • Xilloc: Dutch company specializing in 3D-printed patient-specific implants for cranial, orthopedic, and reconstructive surgery. Direct peer to INNOTERE's Patient-Specific Implants offering.
  • Kasios: French manufacturer of synthetic bone graft substitutes including calcium phosphate cements and TCP-based products for spine, trauma, and dental surgery. Direct peer in synthetic bone void fillers.
  • Curasan: German manufacturer of bone regeneration materials, including synthetic bone graft substitutes and dental bone replacement products. Comparable to INNOTERE's bone void-filler portfolio with a focus on dental/orthopedic use.
  • Biomatlante: Specialist in calcium phosphate-based bone substitutes and macroporous scaffolds for orthopedic and dental surgery. Closely comparable to INNOTERE's calcium phosphate cement and 3D scaffold portfolio.
  • Noraker: French manufacturer of synthetic calcium phosphate bone graft substitutes (MBCP technology) for orthopedic, spinal, and dental indications. Direct peer given shared calcium phosphate cement platform and bone void-filler focus.
  • Bonalive Biomaterials: Finnish company producing bioactive glass and synthetic bone graft substitutes for orthopedic and dental bone regeneration. Comparable as a niche European synthetic bone-substitute specialist.
  • Botiss Biomaterials: Provider of bone and soft tissue regeneration materials, including synthetic bone graft substitutes and 3D-printed scaffolds for dental and orthopedic applications. Direct overlap in synthetic bone substitutes and 3D scaffolds.

Broad incumbents

  • Stryker (Orthobiologics): Global orthopedic medical device leader with a broad orthobiologics portfolio (bone graft substitutes, regenerative materials). Comparable as a large incumbent selling into the same hospital channels as INNOTERE.
  • Bioventus: Pure-play orthobiologics company offering bone graft substitutes, hyaluronic acid, and ultrasonic bone healing products. Comparable as a focused orthobiologics incumbent competing in bone repair and regeneration.
  • Medtronic (Orthobiologics): Diversified medical device giant with a substantial orthobiologics and spine business, including bone graft substitutes. Comparable as a broad incumbent competing in the same bone repair indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

INNOTERE social profiles

Digital presence

INNOTERE compliance and trust

Trust signal

Compliance2 records

INNOTERE financial estimates

Financial estimate

Revenue estimate

Valuation estimate

INNOTERE leadership team

Management profile

Number of profiles

Profiles1 record

INNOTERE funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

INNOTERE M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about INNOTERE

What does INNOTERE do?

INNOTERE GmbH develops and manufactures calcium phosphate-based bone substitute materials and 3D-printed scaffolds for human and veterinary orthopedics. Its portfolio spans ready-to-use injectable Paste-CPC bone cement, macroporous 3D scaffolds, patient-specific implants derived from CT data, and medical-grade calcium phosphate powders (Alpha-TCP, Beta-TCP, Hydroxyapatite). The company also supplies 3D-printing materials and offers medical device regulatory consulting.

Is INNOTERE a public or private company?

INNOTERE is a private company. It is classified as corporate owned and is currently operating.

When was INNOTERE founded?

INNOTERE was founded in 2005. It employs 1 to 10 people.

Where is INNOTERE based?

INNOTERE is headquartered in Radebeul, Germany, in the Europe region.

Who are INNOTERE's main competitors?

Direct peers on record are Xilloc, Kasios, Curasan, Biomatlante, Noraker, Bonalive Biomaterials and Botiss Biomaterials. Broad incumbents are Stryker (Orthobiologics), Bioventus and Medtronic (Orthobiologics).

Does INNOTERE have an API?

No public API is recorded for INNOTERE.

What industry is INNOTERE in?

INNOTERE's product category is Orthobiologic Bone Replacement Materials. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM), with a secondary code of HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials). Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comBiomaterials Market to Reach USD 78.8 Billion by 2035 as Advanced Implants, Regenerative Medicine, and Sustainable Materials Drive Global GrowthMarketGenics Global Research published a report projecting the global biomaterials market to grow from USD 40.8 billion in 2025 to USD 78.8 billion by 2035, representing a compound annual growth rate of 6.8% over the forecast period. The metallic biomaterials segment currently holds approximately 42% market share, driven by orthopedic, dental, and cardiovascular applications, while North America leads regionally and Asia Pacific emerges as the fastest-growing market. Heraeus Medical expanded its regenerative orthopedics portfolio in October 2025 through integration of INNOTERE GmbH, and Covation Biomaterials launched a bio-based alternative called bioPTMEG in April 2025.ElinextExploring Bioprinting SoftwareThis article provides an overview of the bioprinting software market, projecting growth to USD 5.1-5.3 billion by 2030 with a CAGR of 12.5-15.4%, driven by AI-based path planning, cloud collaboration, and medical imaging integration that reportedly reduces printing errors by 30%. It profiles key bioprinting companies across the United States—including Organovo, Allevi, TeVido, Brinter, and CELLINK—and Germany—Cellbricks, MEDPRIN, Black Drop Biodrucker, and INNOTERE—highlighting that the US leads innovation while Germany drives Europe's market expansion expected to reach $649.91 million by 2027. The article emphasizes that advancements in bioprinting software are enabling more precise patient-specific tissue engineering, personalized medicine, and pharmaceutical research applications.PR NewswireInvitation: Press Talk - 3D-Printing: New Possibilities for the IndustryThe State Capital Dresden is hosting a press talk in Hanover to discuss the potential of additive-generative manufacturing and the AGENT-3D project consortium led by the Fraunhofer Institute IWS. The event will feature dialogue with key stakeholders including TU Dresden professors, InnoTere Managing Director Berthold Nies, and officials from the German Society for Material Science. This initiative aims to address obstacles impeding the extensive use of 3D printing in industrial sectors like aerospace and automotive technologies.